Effectiveness of Recombinant Human Growth Hormone Therapy for Children With Phelan-McDermid Syndrome: An Open-Label, Cross-Over, Preliminary Study

BACKGROUND: Phelan-McDermid syndrome (PMS), also known as the 22q13. 3 deletion syndrome, is a rare neurodevelopmental syndrome with approximately 2,800 patients reported worldwide. Previous pilot study demonstrated that IGF-1 could significantly improve in both social impairment and restrictive beh...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, TianXiao, Xie, Ruijin, Zhao, Jinling, Xu, Hua, Cui, Ying, Sun, Chenyu, Wang, Chunhong, Liu, Yueying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888442/
https://www.ncbi.nlm.nih.gov/pubmed/35250656
http://dx.doi.org/10.3389/fpsyt.2022.763565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888442/
https://www.ncbi.nlm.nih.gov/pubmed/35250656
http://dx.doi.org/10.3389/fpsyt.2022.763565

Ejemplares similares